

**Global Lung Cancer Genomic Testing Market By Component (Products v/s Services),  
By Technology (Next Generation Sequencing, Polymerase Chain Reactions,  
Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others), By  
Panel Type (Single Panel v/s Multi-Gene Panel), By Sample Type (Tissue Biopsy v/s  
Liquid Biopsy), By End User (Academic & Research Institutions, Hospitals & Clinics,  
Diagnostic Laboratories, Others), and By Region, Competition Forecast and  
Opportunities, 2027**

Market Report | 2022-10-01 | 115 pages | TechSci Research

**AVAILABLE LICENSES:**

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

**Report description:**

The global lung cancer genomic testing market is still at an early stage and is anticipated to witness a steady CAGR in the forecast period, 2023-2027. Factors such as growing awareness and adoption of lung cancer genomic testing and the high prevalence of lung cancer worldwide are the primary drivers for the global lung cancer genomic testing market. The other factors include the high-end investments by the private and public players to facilitate research and development activities to cure lung cancer and the favorable government policies and campaigns to create awareness about different cancer types. Also, the rapid shift of the healthcare system towards precision medicine and diagnostics technology is expected to boost the adoption of lung cancer genomic testing by healthcare facilities to help them make informed decisions.

**Increased Awareness about Lung Cancer Genomic Testing Drives the Market Growth**

The growing popularity of personalized medicine in the healthcare industry is expected to transform the way diseases such as lung cancer are being treated in healthcare facilities. Personalized medicine involves the study of cells obtained from biopsy and observing if there are any genetic mutations that can be linked with the cancer suffering patient. As certain chemotherapy drugs

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

are either more or less effective than the others with specific mutations, genomic testing or molecular analysis can be used to determine which therapies can benefit an individual suffering from cancer. Genetic information obtained through genomic testing is useful to predict the chances of cancer returning to the human body and make other important decisions about surgery or radiation therapy. Samples obtained from people with lung cancer are checked by studying the genetic mutations known to be vital in the development of the disease. Treatment can be personalized, which can prove to be useful for patients and increase the effectiveness of treatment. Therefore, increased awareness about personalized medicine and the benefits obtained from genomic testing is expected to accelerate the global lung cancer genomic testing market growth over the forecast period.

#### High Prevalence of Lung Cancer Boosts the Market Growth

The rising prevalence of lung cancer, and the large number of patients undergoing screening and treatment are increasing the demand for lung cancer genomic testing services worldwide. Lung cancer, including both small cell and non-small cell, is one of the most common kinds of cancer. According to The American Cancer Society, the estimates for lung cancer in the United States in 2022 are about 236,740 new cases of lung cancer and about 130,180 deaths from lung cancer. It generally occur in the old age population and in the people who smoke on a daily basis. Also, according to World Health Organization, cancer is the leading cause of death and accounted for nearly 10 million deaths in 2020, with which lung cancer death cases were 1.80 million across the globe. Therefore, there is a massive demand for technologies that can lower cancer incidence and mortality rate, and the reliability and benefits of genomic testing are expected to propel global lung cancer genomic testing market growth over the next five years.

#### Market Segmentation

The global lung cancer genomic testing market is segmented into component, technology, panel type, sample type, end user, regional distribution, and competitive landscape. Based on component, the market is divided into products v/s services. Based on technology, the market is divided into next generation sequencing, polymerase chain reactions, fluorescence in situ hybridization (FISH)/in situ hybridization (ISH), and others. Based on panel type, the market is divided into single panel v/s multi-gene panel. Based on sample type, the market is divided into tissue biopsy v/s liquid biopsy. Based on end user, the market is divided into academic & research institutions, hospitals & clinics, diagnostic laboratories, others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region. In terms of country, the United States is expected to be a lucrative market due to the early adoption of advanced technologies by the healthcare sector and the high prevalence of lung cancer in the country.

#### Market Players

Qiagen NV, Agilent Technologies, Inc., Thermo Fischer Scientific, Inc., Quest Diagnostics, Inc., Laboratory Corporation of America Holdings, Centogene N.V., CeGaT GmbH, Illumina, Inc., F. Hoffmann-La Roche AG, Abbott Laboratories, Inc., CD Genomics, NeoGenomics Laboratories, OPKO Health, Inc., OncoDNA, Admera Health are the major market players operating in the global lung cancer genomic testing market.

#### Report Scope:

In this report, global lung cancer genomic testing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

-□ Lung Cancer Genomic Testing Market, By Component:

o□ Products

o□ Services

-□ Lung Cancer Genomic Testing Market, By Technology:

o□ Next Generation Sequencing

o□ Polymerase Chain Reactions

o□ Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)

o□ Others

-□ Lung Cancer Genomic Testing Market, By Panel Type:

o□ Single Panel

o□ Multi-Gene Panel

-□ Lung Cancer Genomic Testing Market, By Sample Type:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Tissue Biopsy
- o Liquid Biopsy
- Lung Cancer Genomic Testing Market, By End User:
  - o Academic & Research Institutions
  - o Hospitals & Clinics
  - o Diagnostic Laboratories
  - o Others
- Lung Cancer Genomic Testing Market, By Region:
  - o North America
    - United States
    - Mexico
    - Canada
  - o Asia-Pacific
    - China
    - India
    - Japan
    - Australia
    - South Korea
  - o Europe
    - Germany
    - France
    - United Kingdom
    - Spain
    - Italy
    - Denmark
    - Netherlands
  - o South America
    - Brazil
    - Argentina
    - Colombia
  - o Middle East & Africa
    - South Africa
    - UAE
    - Saudi Arabia
    - Turkey

#### Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global lung cancer genomic testing market.

#### Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

#### Company Information

- Detailed analysis and profiling of additional market players (up to five).

#### **Table of Contents:**

1. Service Overview
2. Research Methodology
3. Executive Summary

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4. Impact of COVID-19 on Global Lung Cancer Genomic Testing Market
5. Voice of Customer
  - 5.1. Lung Cancer Prevalence, By Type
  - 5.2. Lung Cancer Prevalence, By Gender
  - 5.3. Lung Cancer Prevalence, By Age Group
  - 5.4. Lung Cancer Prevalence, By Region
  - 5.5. Causes of Lung Cancer
6. Clinical Trial Analysis
7. Patent Analysis
8. Global Lung Cancer Genomic Testing Market Outlook
  - 8.1. Market Size & Forecast
    - 8.1.1. By Value
  - 8.2. Market Share & Forecast
    - 8.2.1. By Component (Products v/s Services)
      - 8.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)
      - 8.2.3. By Panel Type (Single Panel v/s Multi-Gene Panel)
      - 8.2.4. By Sample Type (Tissue Biopsy v/s Liquid Biopsy)
      - 8.2.5. By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)
    - 8.2.6. By Company (2021)
    - 8.2.7. By Region
  - 8.3. Product Market Map
9. North America Lung Cancer Genomic Testing Market Outlook
  - 9.1. Market Size & Forecast
    - 9.1.1. By Value
  - 9.2. Market Share & Forecast
    - 9.2.1. By Component
      - 9.2.2. By Technology
        - 9.2.3. By Panel Type
        - 9.2.4. By Sample Type
        - 9.2.5. By End User
      - 9.2.6. By Country
  - 9.3. Policy & Regulatory Landscape
  - 9.4. North America: Country Analysis
    - 9.4.1. United States Lung Cancer Genomic Testing Market Outlook
      - 9.4.1.1. Market Size & Forecast
        - 9.4.1.1.1. By Value
      - 9.4.1.2. Market Share & Forecast
        - 9.4.1.2.1. By Component
          - 9.4.1.2.2. By Technology
            - 9.4.1.2.3. By Panel Type
            - 9.4.1.2.4. By Sample Type
            - 9.4.1.2.5. By End User
      - 9.4.2. Mexico Lung Cancer Genomic Testing Market Outlook
        - 9.4.2.1. Market Size & Forecast
          - 9.4.2.1.1. By Value
        - 9.4.2.2. Market Share & Forecast

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.2.2.1. By Component
- 9.4.2.2.2. By Technology
- 9.4.2.2.3. By Panel Type
- 9.4.2.2.4. By Sample Type
- 9.4.2.2.5. By End User
- 9.4.3. Canada Lung Cancer Genomic Testing Market Outlook
  - 9.4.3.1. Market Size & Forecast
    - 9.4.3.1.1. By Value
  - 9.4.3.2. Market Share & Forecast
    - 9.4.3.2.1. By Component
    - 9.4.3.2.2. By Technology
    - 9.4.3.2.3. By Panel Type
    - 9.4.3.2.4. By Sample Type
    - 9.4.3.2.5. By End User
- 10. Europe Lung Cancer Genomic Testing Market Outlook
  - 10.1. Market Size & Forecast
    - 10.1.1. By Value
  - 10.2. Market Share & Forecast
    - 10.2.1. By Component
    - 10.2.2. By Technology
    - 10.2.3. By Panel Type
    - 10.2.4. By Sample Type
    - 10.2.5. By End User
    - 10.2.6. By Country
  - 10.3. Policy & Regulatory Landscape
  - 10.4. Europe: Country Analysis
    - 10.4.1. France Lung Cancer Genomic Testing Market Outlook
      - 10.4.1.1. Market Size & Forecast
        - 10.4.1.1.1. By Value
      - 10.4.1.2. Market Share & Forecast
        - 10.4.1.2.1. By Component
        - 10.4.1.2.2. By Technology
        - 10.4.1.2.3. By Panel Type
        - 10.4.1.2.4. By Sample Type
        - 10.4.1.2.5. By End User
    - 10.4.2. Germany Lung Cancer Genomic Testing Market Outlook
      - 10.4.2.1. Market Size & Forecast
        - 10.4.2.1.1. By Value
      - 10.4.2.2. Market Share & Forecast
        - 10.4.2.2.1. By Component
        - 10.4.2.2.2. By Technology
        - 10.4.2.2.3. By Panel Type
        - 10.4.2.2.4. By Sample Type
        - 10.4.2.2.5. By End User
    - 10.4.3. United Kingdom Lung Cancer Genomic Testing Market Outlook
      - 10.4.3.1. Market Size & Forecast
        - 10.4.3.1.1. By Value

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.4.3.2.□Market Share & Forecast
  - 10.4.3.2.1.□By Component
  - 10.4.3.2.2.□By Technology
  - 10.4.3.2.3.□By Panel Type
  - 10.4.3.2.4.□By Sample Type
  - 10.4.3.2.5.□By End User
- 10.4.4.□Italy Lung Cancer Genomic Testing Market Outlook
  - 10.4.4.1.□Market Size & Forecast
    - 10.4.4.1.1.□By Value
  - 10.4.4.2.□Market Share & Forecast
    - 10.4.4.2.1.□By Component
    - 10.4.4.2.2.□By Technology
    - 10.4.4.2.3.□By Panel Type
    - 10.4.4.2.4.□By Sample Type
    - 10.4.4.2.5.□By End User
  - 10.4.5.□Spain Lung Cancer Genomic Testing Market Outlook
    - 10.4.5.1.□Market Size & Forecast
      - 10.4.5.1.1.□By Value
    - 10.4.5.2.□Market Share & Forecast
      - 10.4.5.2.1.□By Component
      - 10.4.5.2.2.□By Technology
      - 10.4.5.2.3.□By Panel Type
      - 10.4.5.2.4.□By Sample Type
      - 10.4.5.2.5.□By End User
    - 10.4.6.□Denmark Lung Cancer Genomic Testing Market Outlook
      - 10.4.6.1.□Market Size & Forecast
        - 10.4.6.1.1.□By Value
      - 10.4.6.2.□Market Share & Forecast
        - 10.4.6.2.1.□By Component
        - 10.4.6.2.2.□By Technology
        - 10.4.6.2.3.□By Panel Type
        - 10.4.6.2.4.□By Sample Type
        - 10.4.6.2.5.□By End User
      - 10.4.7.□Netherlands Lung Cancer Genomic Testing Market Outlook
        - 10.4.7.1.□Market Size & Forecast
          - 10.4.7.1.1.□By Value
        - 10.4.7.2.□Market Share & Forecast
          - 10.4.7.2.1.□By Component
          - 10.4.7.2.2.□By Technology
          - 10.4.7.2.3.□By Panel Type
          - 10.4.7.2.4.□By Sample Type
          - 10.4.7.2.5.□By End User
      - 11.□Asia-Pacific Lung Cancer Genomic Testing Market Outlook
        - 11.1.□Market Size & Forecast□
          - 11.1.1.□By Value
        - 11.2.□Market Share & Forecast
          - 11.2.1.□By Component

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.2.□By Technology
- 11.2.3.□By Panel Type
- 11.2.4.□By Sample Type
- 11.2.5.□By End User
- 11.2.6.□By Country
- 11.3.□Policy & Regulatory Landscape
- 11.4.□Asia-Pacific: Country Analysis
  - 11.4.1.□China Lung Cancer Genomic Testing Market Outlook
    - 11.4.1.1.□Market Size & Forecast
      - 11.4.1.1.1.□By Value
    - 11.4.1.2.□Market Share & Forecast
      - 11.4.1.2.1.□By Component
      - 11.4.1.2.2.□By Technology
      - 11.4.1.2.3.□By Panel Type
      - 11.4.1.2.4.□By Sample Type
      - 11.4.1.2.5.□By End User
  - 11.4.2.□India Lung Cancer Genomic Testing Market Outlook
    - 11.4.2.1.□Market Size & Forecast
      - 11.4.2.1.1.□By Value
    - 11.4.2.2.□Market Share & Forecast
      - 11.4.2.2.1.□By Component
      - 11.4.2.2.2.□By Technology
      - 11.4.2.2.3.□By Panel Type
      - 11.4.2.2.4.□By Sample Type
      - 11.4.2.2.5.□By End User
  - 11.4.3.□South Korea Lung Cancer Genomic Testing Market Outlook
    - 11.4.3.1.□Market Size & Forecast
      - 11.4.3.1.1.□By Value
    - 11.4.3.2.□Market Share & Forecast
      - 11.4.3.2.1.□By Component
      - 11.4.3.2.2.□By Technology
      - 11.4.3.2.3.□By Panel Type
      - 11.4.3.2.4.□By Sample Type
      - 11.4.3.2.5.□By End User
  - 11.4.4.□Japan Lung Cancer Genomic Testing Market Outlook
    - 11.4.4.1.□Market Size & Forecast
      - 11.4.4.1.1.□By Value
    - 11.4.4.2.□Market Share & Forecast
      - 11.4.4.2.1.□By Component
      - 11.4.4.2.2.□By Technology
      - 11.4.4.2.3.□By Panel Type
      - 11.4.4.2.4.□By Sample Type
      - 11.4.4.2.5.□By End User
  - 11.4.5.□Australia Lung Cancer Genomic Testing Market Outlook
    - 11.4.5.1.□Market Size & Forecast
      - 11.4.5.1.1.□By Value
    - 11.4.5.2.□Market Share & Forecast

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.5.2.1. By Component
- 11.4.5.2.2. By Technology
- 11.4.5.2.3. By Panel Type
- 11.4.5.2.4. By Sample Type
- 11.4.5.2.5. By End User
- 12. South America Lung Cancer Genomic Testing Market Outlook
  - 12.1. Market Size & Forecast
    - 12.1.1. By Value
  - 12.2. Market Share & Forecast
    - 12.2.1. By Component
    - 12.2.2. By Technology
    - 12.2.3. By Panel Type
    - 12.2.4. By Sample Type
    - 12.2.5. By End User
    - 12.2.6. By Country
  - 12.3. Policy & Regulatory Landscape
  - 12.4. South America: Country Analysis
    - 12.4.1. Brazil Lung Cancer Genomic Testing Market Outlook
      - 12.4.1.1. Market Size & Forecast
        - 12.4.1.1.1. By Value
      - 12.4.1.2. Market Share & Forecast
        - 12.4.1.2.1. By Component
        - 12.4.1.2.2. By Technology
        - 12.4.1.2.3. By Panel Type
        - 12.4.1.2.4. By Sample Type
        - 12.4.1.2.5. By End User
      - 12.4.2. Argentina Lung Cancer Genomic Testing Market Outlook
        - 12.4.2.1. Market Size & Forecast
          - 12.4.2.1.1. By Value
        - 12.4.2.2. Market Share & Forecast
          - 12.4.2.2.1. By Component
          - 12.4.2.2.2. By Technology
          - 12.4.2.2.3. By Panel Type
          - 12.4.2.2.4. By Sample Type
          - 12.4.2.2.5. By End User
      - 12.4.3. Colombia Lung Cancer Genomic Testing Market Outlook
        - 12.4.3.1. Market Size & Forecast
          - 12.4.3.1.1. By Value
        - 12.4.3.2. Market Share & Forecast
          - 12.4.3.2.1. By Component
          - 12.4.3.2.2. By Technology
          - 12.4.3.2.3. By Panel Type
          - 12.4.3.2.4. By Sample Type
          - 12.4.3.2.5. By End User
  - 13. Middle East and Africa Lung Cancer Genomic Testing Market Outlook
    - 13.1. Market Size & Forecast
      - 13.1.1. By Value

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.2. Market Share & Forecast
  - 13.2.1. By Component
  - 13.2.2. By Technology
  - 13.2.3. By Panel Type
  - 13.2.4. By Sample Type
  - 13.2.5. By End User
  - 13.2.6. By Country
- 13.3. Policy & Regulatory Landscape
- 13.4. MEA: Country Analysis
  - 13.4.1. Turkey Lung Cancer Genomic Testing Market Outlook
    - 13.4.1.1. Market Size & Forecast
      - 13.4.1.1.1. By Value
      - 13.4.1.1.2. Market Share & Forecast
        - 13.4.1.1.2.1. By Component
        - 13.4.1.1.2.2. By Technology
        - 13.4.1.1.2.3. By Panel Type
        - 13.4.1.1.2.4. By Sample Type
        - 13.4.1.1.2.5. By End User
    - 13.4.1.2. South Africa Lung Cancer Genomic Testing Market Outlook
      - 13.4.1.2.1. Market Size & Forecast
        - 13.4.1.2.1.1. By Value
        - 13.4.1.2.2. Market Share & Forecast
          - 13.4.1.2.2.1. By Component
          - 13.4.1.2.2.2. By Technology
          - 13.4.1.2.2.3. By Panel Type
          - 13.4.1.2.2.4. By Sample Type
          - 13.4.1.2.2.5. By End User
      - 13.4.1.3. Saudi Arabia Lung Cancer Genomic Testing Market Outlook
        - 13.4.1.3.1. Market Size & Forecast
          - 13.4.1.3.1.1. By Value
          - 13.4.1.3.2. Market Share & Forecast
            - 13.4.1.3.2.1. By Component
            - 13.4.1.3.2.2. By Technology
            - 13.4.1.3.2.3. By Panel Type
            - 13.4.1.3.2.4. By Sample Type
            - 13.4.1.3.2.5. By End User
        - 13.4.1.4. UAE Lung Cancer Genomic Testing Market Outlook
          - 13.4.1.4.1. Market Size & Forecast
            - 13.4.1.4.1.1. By Value
            - 13.4.1.4.2. Market Share & Forecast
              - 13.4.1.4.2.1. By Component
              - 13.4.1.4.2.2. By Technology
              - 13.4.1.4.2.3. By Panel Type
              - 13.4.1.4.2.4. By Sample Type
              - 13.4.1.4.2.5. By End User
      - 14. Market Dynamics
        - 14.1. Drivers

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.2. □Challenges
- 15. □Market Trends & Developments
- 16. □SWOT Analysis: Global Lung Cancer Genomic Testing Market
- 17. □Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)
- 17.1. □Qiagen NV
- 17.2. □Agilent Technologies, Inc.
- 17.3. □Thermo Fischer Scientific, Inc.
- 17.4. □Quest Diagnostics, Inc.
- 17.5. □Laboratory Corporation of America Holdings
- 17.6. □Centogene N.V.
- 17.7. □CeGaT GmbH
- 17.8. □Illumina, Inc.
- 17.9. □F. Hoffmann-La Roche AG
- 17.10. □Abbott Laboratories, Inc.
- 17.11. □CD Genomics
- 17.12. □NeoGenomics Laboratories
- 17.13. □OPKO Health, Inc.
- 17.14. □OncoDNA
- 17.15. □Admera Health
- 18. □Strategic Recommendations

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Global Lung Cancer Genomic Testing Market By Component (Products v/s Services),  
By Technology (Next Generation Sequencing, Polymerase Chain Reactions,  
Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others), By  
Panel Type (Single Panel v/s Multi-Gene Panel), By Sample Type (Tissue Biopsy v/s  
Liquid Biopsy), By End User (Academic & Research Institutions, Hospitals & Clinics,  
Diagnostic Laboratories, Others), and By Region, Competition Forecast and  
Opportunities, 2027**

Market Report | 2022-10-01 | 115 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00
	Custom Research License	\$8900.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email\*

Phone\*

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>